Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €167.63 EUR
Change Today +0.95 / 0.57%
Volume 7.8K
SRT3 On Other Exchanges
As of 3:35 PM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

sartorius ag-vorzug (SRT3) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/25/15 - €174.00
52 Week Low
10/16/14 - €75.44
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SARTORIUS AG-VORZUG (SRT3)

Related News

No related news articles were found.

sartorius ag-vorzug (SRT3) Related Businessweek News

No Related Businessweek News Found

sartorius ag-vorzug (SRT3) Details

Sartorius Aktiengesellschaft provides laboratory and process technologies and equipment primarily in Europe, North America, and the Asia Pacific. The company operates through Bioprocess Solutions, and Lab Products & Services segments. The Bioprocess Solutions segment offers products, technologies, and services ranging from fermentation, cell cultivation, filtration, and purification to media storage and transportation for the biopharmaceutical industry. It offers filters for liquids, air/gas filters, filter housings, filter integrity testing products, and OEM membranes; single-use bioprocess bags, containers, mixing systems, aseptic transfer systems, freeze and thaw systems, and tubing dis-/connectors; crossflow holders and systems, crossflow filters, membrane chromatography, clarification filters, virus filters, UV-C inactivation systems, and endonuclease; process analyzers, process control tools, microbiology products, and chemometric software; and media USP, media and buffer DSP, bioreactors/fermentors, and configurable single-use systems. The Lab Products & Services segment provides laboratory instruments, such as lab balances, pipettes, and laboratory water purification systems; and consumables, including laboratory filters and pipette tips. Its products include OEM weigh cells, mass comparators and metrology, weights/weight sets, paint mixing solutions, microbiology products, and moisture analyzers; lab water systems; bioreactors/fermentors, shakers/incubators, cell culture disposables, and centrifuges; and filters, ultrafiltration and membrane chromatography products, virus purification kits, diagnostic membranes and arrays, and blotting membranes. This segment also offers instrument and training services. It serves research and quality assurance laboratories of the pharmaceutical, chemical, and food industries. Sartorius Aktiengesellschaft was founded in 1870 and is headquartered in Goettingen, Germany.

5,611 Employees
Last Reported Date: 02/28/15
Founded in 1870

sartorius ag-vorzug (SRT3) Top Compensated Officers

Chairman of Executive Board and Group Chief E...
Total Annual Compensation: €1.0M
Member of the Executive Board
Total Annual Compensation: €615.0K
Member of the Executive Board
Total Annual Compensation: €435.0K
Compensation as of Fiscal Year 2014.

sartorius ag-vorzug (SRT3) Key Developments

Sartorius Aktiengesellschaft Presents at Deutsche Bank dbAccess German, Swiss & Austrian Conference 2015, Jun-17-2015

Sartorius Aktiengesellschaft Presents at Deutsche Bank dbAccess German, Swiss & Austrian Conference 2015, Jun-17-2015 . Venue: Berlin, Germany.

Sartorius Reports Group Earnings Results for the First Quarter of 2015; Provides Earnings Guidance for the Full Year of 2015

Sartorius reported Group earnings results for the first quarter of 2015. For the quarter, the company reported sales revenue of EUR 258.1 million compared to EUR 203.1 million a year ago. EBITDA was EUR 57.5 million compared to EUR 38.7 million a year ago. EBITDA margin was 22.3% compared to 19.0% a year ago. Relavant net profit was EUR 22.1 million compared to EUR 13.3 million a year ago. Earnings per ordinary share were EUR 1.29 compared to EUR 0.77 a year ago. Earnings per preference share were EUR 1.31 compared to EUR 0.79 a year ago. For the full year 2015, based on the results of the first quarter in 2015, management revised its sales and earnings forecast upwards. The company thus expects sales to increase approximately 6% to 9% in constant currencies instead of 4% to 7% forecasted at the beginning of the year. The company's underlying EBITDA margin is projected to reach around 22% in constant currencies; previously, around 21.5% was anticipated. Sartorius continues to plan on investing around 10% of its sales revenue. The company now expects that sales for Bioprocess Solutions will grow approximately 8% to 11% in constant currencies (previous guidance approximately 5% to 8%) and that its underlying EBITDA margin will rise to around 25.0% (previous guidance approximately 24.5%). For the Lab Products & Services Division, management confirms its current forecast, which projects that the division's sales revenue will rise about 2% to 5% and its underlying EBITDA margin will increase to around 15.5%.

Sartorius Group Reports Sales Results for the First Quarter of 2015; Provides Earnings Guidance for the Full Year 2015

Sartorius Group reported sales results for the first quarter of 2015. For the quarter the company achieved sales growth of around 17% in constant currencies based on preliminary figures, reaching approximately EUR 258 million in consolidated revenue, this growth was driven primarily by the Bioprocess Solutions Division. Due to the low prior-year revenue base, the company had expected above-average growth rates for this first quarter. For the full year of 2015, the company sales revenue in constant currencies expected to increase by approximately 6% to 9% against previous guidance: approx. 4% to 7%. Management projects that the company's underlying EBITDA margin in constant currencies will increase to around 22% against previous guidance: around 21.5%.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SRT3:GR €167.63 EUR +0.95

SRT3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CLARCOR Inc $62.26 USD -0.01
Donaldson Co Inc $35.70 USD -0.04
ESCO Technologies Inc $37.08 USD -0.63
Mettler-Toledo International Inc $346.46 USD +1.50
Pall Corp $124.96 USD +0.15
View Industry Companies

Industry Analysis


Industry Average

Valuation SRT3 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow 18.9x
TEV/Sales 1.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SARTORIUS AG-VORZUG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at